These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28973027)

  • 1. Plant-expressed pyocins for control of Pseudomonas aeruginosa.
    Paškevičius Š; Starkevič U; Misiūnas A; Vitkauskienė A; Gleba Y; Ražanskienė A
    PLoS One; 2017; 12(10):e0185782. PubMed ID: 28973027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of FiuA Outer Membrane Receptor Polymorphism on the Resistance of
    Latino L; Patin D; Chérier D; Touzé T; Pourcel C; Barreteau H; Mengin-Lecreulx D
    J Bacteriol; 2019 Jul; 201(13):. PubMed ID: 30988031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Colicin M-Type Bacteriocin from Pseudomonas aeruginosa Targeting the HxuC Heme Receptor Requires a Novel Immunity Partner.
    Ghequire MGK; Öztürk B
    Appl Environ Microbiol; 2018 Sep; 84(18):. PubMed ID: 29980560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogenous Susceptibility to R-Pyocins in Populations of Pseudomonas aeruginosa Sourced from Cystic Fibrosis Lungs.
    Mei M; Thomas J; Diggle SP
    mBio; 2021 May; 12(3):. PubMed ID: 33947755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and functional analysis of a bacteriocin, pyocin S6, with ribonuclease activity from a Pseudomonas aeruginosa cystic fibrosis clinical isolate.
    Dingemans J; Ghequire MG; Craggs M; De Mot R; Cornelis P
    Microbiologyopen; 2016 Jun; 5(3):413-23. PubMed ID: 26860427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F-Type Pyocins Are Diverse Noncontractile Phage Tail-Like Weapons for Killing
    Saha S; Ojobor CD; Li ASC; Mackinnon E; North OI; Bondy-Denomy J; Lam JS; Ensminger AW; Maxwell KL; Davidson AR
    J Bacteriol; 2023 Jun; 205(6):e0002923. PubMed ID: 37260386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competition in Biofilms between Cystic Fibrosis Isolates of
    Oluyombo O; Penfold CN; Diggle SP
    mBio; 2019 Jan; 10(1):. PubMed ID: 30696740
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antibiotic sensitivity and pyocin dependence of clinical strains of Ps. aeruginosa].
    Savitskaia KI; Levina EN
    Antibiotiki; 1977 Dec; 22(12):1117-21. PubMed ID: 413475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. O serotype-independent susceptibility of Pseudomonas aeruginosa to lectin-like pyocins.
    Ghequire MG; Dingemans J; Pirnay JP; De Vos D; Cornelis P; De Mot R
    Microbiologyopen; 2014 Dec; 3(6):875-84. PubMed ID: 25224846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudomonas aeruginosa Soluble Pyocins as Antibacterial Weapons.
    Cornelis P; Dingemans J; Baysse C
    Methods Mol Biol; 2024; 2721():125-136. PubMed ID: 37819519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of pyocin S2 against Pseudomonas aeruginosa biofilms.
    Smith K; Martin L; Rinaldi A; Rajendran R; Ramage G; Walker D
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1599-601. PubMed ID: 22183174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relations between antibiotic resistance and pyocin P3 resistance in Pseudomonas aeruginosa mutants].
    García-Quintana HG; Wilckens R
    Zentralbl Veterinarmed B; 1983 Apr; 30(3):169-74. PubMed ID: 6408850
    [No Abstract]   [Full Text] [Related]  

  • 13. [Bactericidal spectrum of pyocins on strains collected at Region IX and X hospitals in Chile].
    García-Quintana HG; Polette M; Ríos J
    Rev Med Chil; 1989 Jun; 116(6):543-8. PubMed ID: 2501848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility to R-pyocins of Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients.
    Redero M; López-Causapé C; Aznar J; Oliver A; Blázquez J; Prieto AI
    J Antimicrob Chemother; 2018 Oct; 73(10):2770-2776. PubMed ID: 30052973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of bacteriocin production by clinical Pseudomonas aeruginosa isolates and their potential as therapeutic agents.
    Charkhian H; Soleimannezhadbari E; Bodaqlouei A; Lotfollahi L; Lotfi H; Yousefi N; Shojadel E; Gholinejad Z
    Microb Cell Fact; 2024 Jun; 23(1):175. PubMed ID: 38872163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Possible use of pyocins against Pseudomonas aeruginosa (author's transl)].
    Sezen IY; Blobel H; Scharmann W
    Zentralbl Bakteriol Orig A; 1974; 229(2):205-8. PubMed ID: 4155865
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of species-specific protein antibiotics in a murine model of acute Pseudomonas aeruginosa lung infection.
    McCaughey LC; Ritchie ND; Douce GR; Evans TJ; Walker D
    Sci Rep; 2016 Jul; 6():30201. PubMed ID: 27444885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Killing of Pseudomonas aeruginosa by Pyocin G Occurs via the Hemin Transporter Hur.
    Atanaskovic I; Mosbahi K; Sharp C; Housden NG; Kaminska R; Walker D; Kleanthous C
    J Mol Biol; 2020 Jun; 432(13):3869-3880. PubMed ID: 32339530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of resistance phenotype to the R-pyocin susceptibility pattern in clinical isolates of Pseudomonas aeruginosa.
    Petrocheilou-Malliara K; Koukoubanis N; Legakis N
    Chemioterapia; 1987 Jun; 6(2 Suppl):199. PubMed ID: 3151341
    [No Abstract]   [Full Text] [Related]  

  • 20. Discovery, characterization and in vivo activity of pyocin SD2, a protein antibiotic from Pseudomonas aeruginosa.
    McCaughey LC; Josts I; Grinter R; White P; Byron O; Tucker NP; Matthews JM; Kleanthous C; Whitchurch CB; Walker D
    Biochem J; 2016 Aug; 473(15):2345-58. PubMed ID: 27252387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.